AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
CytarabineIdarubicinDaunorubicinLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsRemission InductionConsolidation ChemotherapyMitoxantroneAntimetabolites, AntineoplasticArabinonucleosidesEtoposideLeukemia, MyeloidDrug Administration ScheduleThioguanineTreatment OutcomeMethotrexateVincristineInduction ChemotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaMeningeal CarcinomatosisInjections, SpinalLeukemic InfiltrationAcute DiseaseCyclophosphamideDisease-Free SurvivalCarmustineCytidine MonophosphateSurvival AnalysisAsparaginaseLymphoma, Non-HodgkinDrug Agonism6-MercaptopurineSurvival RateDeoxycytidine KinaseLeukemia, Myelomonocytic, AcuteRecurrenceArabinonucleotidesSalvage TherapyLeukemia, Myeloid, Accelerated PhaseVidarabineCentral Nervous System NeoplasmsTransplantation, AutologousAmsacrineDoxorubicinInfusions, IntravenousArabinofuranosylcytosine TriphosphateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCombined Modality TherapyDexamethasoneTeniposideAnemia, Refractory, with Excess of BlastsMyelodysplastic SyndromesAntineoplastic AgentsDose-Response Relationship, DrugMelphalanLeukemiaMeningitisDrug Resistance, NeoplasmCladribinePrednisonePodophyllotoxinBlast CrisisLeukemia, Myeloid, Chronic-PhaseGranulocyte Colony-Stimulating FactorPrognosisAdenine NucleotidesDioxolanesHematopoietic Stem Cell TransplantationActuarial AnalysisPolyradiculopathyHarringtoninesAclarubicinTime FactorsCytogenetic AnalysisPyrimidinesBenzamidesBurkitt LymphomaMeningesPiperazinesBone Marrow TransplantationEquilibrative Nucleoside Transporter 1CisplatinAntibodies, Monoclonal, Murine-DerivedLymphoma, Mantle-CellCore Binding FactorsLeukemia, Promyelocytic, AcuteAminoglycosidesDrug SynergismMaximum Tolerated DoseDrug EvaluationLeukoencephalopathy, Progressive MultifocalAzacitidineAnthracyclinesNauseaProspective StudiesLymphomaInterferon-alphaIfosfamidePapilledemaNeutropenia
ChemotherapyDexamethasoneAllogeneic stem cell transIntravenouslyHigh-doseCISPLATINTherapyRegimenPatientsRepeatsDrugsTreatmentWeeksMinutesWeekFormAdministrationDaunorubicinIntrathecallyInfusionLiposomalDoseContinuousDosesInjectionInduction therapyIdarubicinPatientsLeukemiaCyclesAssessRemissionDailyClinicalActiveTreatmentHoursComplete
Chemotherapy4
  • Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. (mycancergenome.org)
  • Administer EMEND 1 hour prior to chemotherapy on Days 1, 2, and 3. (nih.gov)
  • If no chemotherapy is given on Days 2 and 3, administer EMEND in morning. (nih.gov)
  • 40 mg/m 2 on day 1 and 30 mg/m 2 on day 8 every 28 days (as part of the VCAP-AMP-VECP multiagent chemotherapy regimen) for 6 cycles (Tsukasaki 2007). (medilib.ir)
Dexamethasone2
Allogeneic stem cell trans1
  • 75 years old) followed by cytarabine consolidations and/or allogeneic stem-cell transplantation (ASCT). (dovepress.com)
Intravenously1
  • Patients receive MEK inhibitor MEK162 orally (PO) twice daily (BID) on days -4 to -1 and days 5-18, cytarabine intravenously (IV) continuously over 24 hours on days 1-4, and idarubicin IV over 1 hour on days 1-3. (mycancergenome.org)
High-dose2
  • INTENSIFICATION THERAPY: Beginning 4 weeks after the completion of course 2 of induction therapy, patients receive intensification therapy comprising high-dose methotrexate IV over 2 hours on days 1 and 8, and pegaspargase IM or IV on day 9. (clinicaltrialsgps.com)
  • alternating cycles with high-dose methotrexate and cytarabine (Kantarjian 2004). (medilib.ir)
CISPLATIN2
  • 40 mg/m 2 on day 1 every 4 weeks (in combination with cisplatin, etoposide, and mitotane) (Fassnacht 2012) or 20 mg/m 2 on days 1 and 8 every 4 weeks (in combination with cisplatin, etoposide, and mitotane) until disease progression or unacceptable toxicity up to a maximum of 6 cycles (Berruti 2005). (medilib.ir)
  • Sternberg 2006) or 30 mg/m 2 on day 1 every 28 days (in combination with methotrexate, vinblastine, cisplatin, and filgrastim) for up to 6 cycles or until loss of clinical benefit (Bamias 2004). (medilib.ir)
Therapy3
  • Patients achieving partial or complete remission may receive a second course of therapy beginning approximately 30 days after the completion of the first course. (knowcancer.com)
  • Assess respiratory status continuously throughout therapy with vecuronium. (unboundmedicine.com)
  • Assess respiratory status continuously throughout therapy with neuromuscular blocking agents. (unboundmedicine.com)
Regimen1
  • IVE will be continuously producing education handouts for each treatment regimen to add to your regimen library. (ivcanceredsheets.com)
Patients7
  • Determine the clinical effectiveness of bevacizumab, cytarabine, and mitoxantrone in patients with poor-risk hematologic malignancies. (knowcancer.com)
  • This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine. (mycancergenome.org)
  • Patients receive cytarabine IV continuously over 24 hours on days 1-3, idarubicin IV over 1 hour on days 1 and 2, and MEK inhibitor MEK 162 PO BID on days 4-17. (mycancergenome.org)
  • After completion of study treatment , patients are followed up for 30 days. (mycancergenome.org)
  • and CD20 positive patients may optionally receive rituximab IV on day 8 and 15. (clinicaltrialsgps.com)
  • EMEND capsules in adults and pediatric patients 12 years of age and older: is 125 mg on Day 1 and 80 mg on Days 2 and 3. (nih.gov)
  • These AZA- and DCA-naive patients treated with AZA 100 mg/(m²·day) for 5 days to 7 days or DAC 20 mg/(m²·day) for 3 days to 4 days, or 20 mg/(m²·day) 1 day/week for 3 weeks/month were assessed for treatment responses and adverse events. (medscimonit.com)
Repeats1
  • Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. (mycancergenome.org)
Drugs1
  • In 1980, 1981, and 1985, and continuously from 1989, the NAMCS encounter form included a question which asked for a listing of all drugs/medications ordered, administered or provided during the visit. (cdc.gov)
Treatment2
Weeks1
  • Most of these side effects may go away within a few days or a couple of weeks. (medicalnewstoday.com)
Minutes1
  • 30-60 minutes on day 4, and bevacizumab IV over 90 minutes on day 8 in the absence of disease progression or unacceptable toxicity. (knowcancer.com)
Week2
  • monitor INR in 2-week period, particularly at 7 to 10 days, following initiation of EMEND. (nih.gov)
  • The prevalence of positive CSF IgM tests increases by about 10% per day after illness onset and reaches 70-80% by the end of the first week. (basicmedicalkey.com)
Form1
  • Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed. (oncotarget.com)
Administration1
  • Efficacy of contraceptives may be reduced during administration of and for 28 days following the last dose of EMEND. (nih.gov)
Daunorubicin13
Intrathecally1
  • Patients receive cytarabine intrathecally (IT) on days -6 to 0 prior to cycle 1. (ucsf.edu)
Infusion1
  • The regimen for induction therapy is the "7 + 3" regimen: Cytarabine at 100 mg/m 2 /d intravenously (IV) by continuous infusion on days 1-7 plus an anthracycline (idarubicin 12 mg/m 2 or commonly used daunorubicin 45-60 mg/ m 2 ) or anthracenedione (mitoxantrone 12 mg/ m 2 ) ( IV) push on days 1-3. (medscape.com)
Liposomal1
  • 6,7 Vyxeos liposomal (CPX-351) is a dual-drug liposomal encapsulation of cytarabine and daunorubicine at a fixed 5:1 synergetic molar ratio. (bjh.be)
Dose6
  • The high-dose ara-C (HiDAC) regimen includes cytarabine at 3 g/m 2 IV q12h on days 1, 3, and 5 for 4 cycles. (medscape.com)
  • 7 days or one dose of pegfilgrastim on day 9. (uchicagomedicine.org)
  • Consolidation phase: Subjects who achieved CR or CRi with adequate blood count recovery after induction with one or two cycles of induction proceeded to consolidation therapy with either 3 or 4 cycles respectively of intermediate-dose cytarabine (D1 - D3), or to Hematopoietic Stem Cells Transplantation (HSCT) with or without preceding consolidation cycles. (survivornet.com)
  • Diltiazem dose should not exceed 240 mg/day and simvastatin dose should not exceed 10 mg/day. (unboundmedicine.com)
  • The efficacy of hormonal contraceptives during and for 28 days following the last dose of EMEND may be reduced. (nih.gov)
  • Patients in the study, who were under age 70, received a daily oral dose of 420 mg of ibrutinib (Imbruvica, Janssen) for 3 cycles (28 days each), followed by 12 cycles of ibrutinib with an escalating dose of venetoclax (Venclexta/Venclyxto) up to 400 mg. (ajmc.com)
Continuous1
  • Post-consolidation phase: Subjects who maintained CR or CRi with adequate blood count recovery at the end of the consolidation phase received 12 cycles (28 days/cycle) of continuous therapy with midostaurin or placebo twice daily at 50 mg. (survivornet.com)
Doses2
  • and leucovorin PO calcium every 6 hours for a total of 8 doses each on days 3-4, 17-18, and 31-32. (uchicagomedicine.org)
  • Patients may receive additional doses of cytarabine on day 1 of subsequent cycles per physician discretion. (ucsf.edu)
Injection2
  • DepoCyt ® (cytarabine liposome injection) is indicated for the intrathecal treatment of lymphomatous meningitis. (nih.gov)
  • EMEND (fosaprepitant dimeglumine) for Injection may be substituted for oral EMEND (125 mg) on Day 1 only as part of the CINV regimen. (nih.gov)
Induction therapy5
  • A bone marrow biopsy should be performed 14 days after induction therapy to assess remission status. (medscape.com)
  • Induction therapy: Patients receive oral pravastatin once daily on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. (survivornet.com)
  • Consolidation therapy: Beginning 30-60 days after the start of induction therapy , patients receive oral pravastatin once daily on days 1-6 and idarubicin IV over 10-15 minutes and cytarabine IV continuously on days 4 and 5. (survivornet.com)
  • 3 For more than four decades, the 7+3 regimens ( i.e . cytarabine infused continuously for 7 days with three once-daily injections of an anthracycline) have been the gold standard for AML induction therapy. (bjh.be)
  • Throughout my first few days of that block, I learned about other AML induction therapies-FLT-3 and BCL-2 small-molecule inhibitors, CD33-directed antibody-drug conjugates, IDH2 inhibitors-that had completely upended the generations-long paradigm of induction therapy. (medscape.com)
Idarubicin4
Patients4
  • Patients also receive flotetuzumab IV continuously for 28 days. (ucsf.edu)
  • After completion of study treatment, patients are followed for 30 days. (ucsf.edu)
  • RESULTS: All patients completed IMPT according to the protocol, with a median treatment duration of 43 days (range, 33 to 51 days). (bvsalud.org)
  • In our hospital, we observed two cases of precipitation of etoposide during a 7-month period, both in pediatric patients treated for acute myeloid leukemia according to the DB-AML-01 protocol.9 The precipitation occurred during the AIET induction course (Figure 1) when Eposinti (Teva Pharma) 100mg/m2 was administered continuously for 4 days in a concentration of 0.4mg/mL. (phosphorylaseinhibitors.com)
Leukemia1
Cycles2
  • Treatment repeats every 29 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. (ucsf.edu)
  • Subjects who underwent HSCT after achieving CR or CRi with adequate blood count recovery received midostaurin or placebo twice daily 50 mg post-transplant therapy, continuously, for up to 12 cycles (28 days/cycle). (survivornet.com)
Assess1
  • Assess respiratory status continuously throughout therapy with vecuronium. (unboundmedicine.com)
Remission1
  • 7 + 3 requires a 19- to 28-day stay in a hospital (or sometimes longer), depending upon how well the side effects are tolerated and whether a remission is achieved. (chemoexperts.com)
Daily1
  • Labs (blood tests) may be checked before treatment, then daily or every other day for the first few weeks while in the hospital. (chemoexperts.com)
Clinical1
  • Compounds from marine organisms (e.g. trabectedin, cytarabine, and eribulin mesylate) have been approved for clinical trials and cancer treatment [ 5 - 7 ]. (oncotarget.com)
Active1
  • Hypersensitive to cytarabine or any component of the formulation with active meningeal infection. (nih.gov)
Treatment1
  • This would have been daunting if I had walked into this new treatment environment on day 1 of fellowship. (medscape.com)
Hours1
  • Cytarabine is infused continuously for 168 hours (Days 1 through 7). (chemoexperts.com)
Complete1
  • Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed. (oncotarget.com)